Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Sep 2;13(9):2078-2085.
doi: 10.1080/21645515.2017.1342021. Epub 2017 Jul 14.

Open-label phase I clinical trial of Ad5-EBOV in Africans in China

Lihua Wu  1   2 , Zhe Zhang  3 , Hainv Gao  2   4 , Yuhua Li  5 , Lihua Hou  3 , Hangping Yao  1   2 , Shipo Wu  3 , Jian Liu  1   2 , Ling Wang  5 , You Zhai  1   2 , Huilin Ou  1   2 , Meihua Lin  1   2 , Xiaoxin Wu  2   4 , Jingjing Liu  5 , Guanjing Lang  1   2 , Qian Xin  6 , Guolan Wu  1   2 , Li Luo  7 , Pei Liu  7 , Jianzhong Shentu  1   2 , Nanping Wu  1   2 , Jifang Sheng  1   2 , Yunqing Qiu  1   2 , Wei Chen  3 , Lanjuan Li  1   2   4
Affiliations
Clinical Trial

Open-label phase I clinical trial of Ad5-EBOV in Africans in China

Lihua Wu et al. Hum Vaccin Immunother. .

Abstract

Background: To determine the safety and immunogenicity of a novel recombinant adenovirus type 5 vector based Ebola virus disease vaccine (Ad5-EBOV) in Africans in China.

Methods: A phase 1, dose-escalation, open-label trial was conducted. 61 healthy Africans were sequentially enrolled, with 31 participants receiving one shot intramuscular injection and 30 participants receiving a double-shot regimen. Primary and secondary end points related to safety and immunogenicity were assessed within 28 d after vaccination. This study was registered with ClinicalTrials.gov (NCT02401373).

Results: Ad5-EBOV is well tolerated and no adverse reaction of grade 3 or above was observed. 53 (86.89%) participants reported at least one adverse reaction within 28 d of vaccination. The most common reaction was fever and the mild pain at injection site, and there were no significant difference between these 2 groups. Ebola glycoprotein-specific antibodies appeared in all 61 participants and antibodies titers peaked after 28 d of vaccination. The geometric mean titres (GMTs) were similar between these 2 groups (1919.01 vs 1684.70 P = 0.5562). The glycoprotein-specific T-cell responses rapidly peaked after 14 d of vaccination and then decreased, however, the percentage of subjects with responses were much higher in the high-dose group (60.00% vs 9.68%, P = 0.0014). Pre-existing Ad5 neutralizing antibodies could significantly dampen the specific humoral immune response and cellular response to the vaccine.

Conclusion: The application of Ad5-EBOV demonstrated safe in Africans in China and a specific GP antibody and T-cell response could occur 14 d after the first immunization. This acceptable safety profile provides a reliable basis to proceed with trials in Africa.

Keywords: Ad5-EBOV; GP antibody; T-cell response; immunogenicity; safety.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Screening, enrollment, vaccinations, and follow-up in the study. The low dose group and high dose group were enrolled sequentially according to a dose­escalation protocol. All the 61 participants completed the study­injection regimen and 28 d of follow­up. All available study data were used for final analysis.
Figure 2.
Figure 2.
Glycoprotein-specific T-cell response measured by Enzyme-Linked ImmunoSpot at different time points pre- and post-vaccination. IFN-γ expressing T-cells per 106 PBMC in the all participants (A, n = 31 in the low dose group and n = 30 in the high dose group), and those with pre-existing adenovirus type-5 neutralising antibody titres ≤ 1:200 (B, n = 13 in the low dose group and n = 9 in the high dose group) or >1:200 (C, n = 18 in the low dose group and n = 21 in the high dose group). Cases with undetected T cell response were not shown. The line at median with 75th percentiles (3rd quatile, Q3) were shown in the figure. IFN = interferon. PBMC = peripheral blood mononuclear cells.
Figure 3.
Figure 3.
Glycoprotein-specific T-cell response measured by flow cytometry with intracellular cytokine staining (ICS) at different time points pre- and post-vaccination. CD4 T-cell response in all participants (A, n = 31 in the low dose group and n = 30 in the high dose group) and those with pre-existing adenovirus type-5 neutralising antibody titres ≤1:200 (B, n = 13 in the low dose group and n = 9 in the high dose group) or >1:200 (C, n = 18 in the low dose group and n = 21 in the high dose group), and CD8 T-cell response in all participants (D, n = 31 in the low dose group and n = 30 in the high dose group) and those with pre-existing adenovirus type-5 neutralising antibody titres ≤1:200 (E, n = 13 in the low dose group and n = 9 in the high dose group) or >1:200 (F, n = 18 in the low dose group and n = 21 in the high dose group). Proportions of glycoprotein-specific CD4 (G) and CD8 (H) cells that produce any combination of the three cytokines at day14 and day 28. TNF = tumour necrosis factor. IL = interleukin. IFN = interferon. Cases with undetected T cell response were not shown. The line at median with 75th percentiles (3rd quatile, Q3) were shown in the Figure.
See this image and copyright information in PMC

References

    1. Nanclares C, Kapetshi J, Lionetto F, de la Rosa O, Tamfun JJ, Alia M, Kobinger G, Bernasconi A. Ebola virus disease, democratic republic of the Congo, 2014. Emerg Infect Dis 2016; 22(9):1579-86; PMID:27533284; https://doi.org/ 10.3201/eid2209.160354 - DOI - PMC - PubMed
    1. Hersey S, Martel LD, Jambai A, Keita S, Yoti Z, Meyer E, Seeman S, Bennett S, Ratto J, Morgan O, et al.. Ebola Virus Disease–Sierra Leone and Guinea, August 2015. MMWR Morb Mortal Wkly Rep 2015; 64(35):981-4; PMID:26355422; https://doi.org/ 10.15585/mmwr.mm6435a6 - DOI - PubMed
    1. Martins KA, Jahrling PB, Bavari S, Kuhn JH. Ebola virus disease candidate vaccines under evaluation in clinical trials. Expert Rev Vaccines 2016; 15(9):1101-12; PMID:27160784; https://doi.org/ 10.1080/14760584.2016.1187566 - DOI - PMC - PubMed
    1. Ledgerwood JE, DeZure AD, Stanley DA, Coates EE, Novik L, Enama ME, Berkowitz NM, Hu Z, Joshi G, Ploquin A, et al.. Chimpanzee adenovirus vector ebola vaccine. N Engl J Med 2017; 376(10):928-38; PMID:25426834; https://doi.org/ 10.1056/NEJMoa1410863 - DOI - PubMed
    1. De Santis O, Audran R, Pothin E, Warpelin-Decrausaz L, Vallotton L, Wuerzner G, Cochet C, Estoppey D, Steiner-Monard V, Lonchampt S, et al.. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis 2016; 16(3):311-20; PMID:26725450; https://doi.org/ 10.1016/S1473-3099(15)00486-7 - DOI - PubMed

Publication types

MeSH terms

Associated data